Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Mon, 10.05.2021
Cryptology Asset Group PLC
Cryptology Asset Group: 'We want to be the leading European investor in
crypto assets and blockchain-based business models'
Cryptology Asset Group is a publicly traded investment company focused on
cryp-to-assets and blockchain-based business models. For this purpose,
Cryptology has a broad network of experts, including Christian Angermayer
and [ … ]
Tue, 04.05.2021
Media and Games Invest plc
Jump in revenue and earnings in the first quarter of 2021; the largest
growth pipeline in the company's history ensures further dynamic growth;
the expected recovery of the advertising market offers additional growth
potential for the Group's own digital advertising division, increase in
forecasts and price target
Turnover and earnings developme [ … ]
Thu, 29.04.2021
MagForce AG
Further results of the pivotal study 2a confirm expectations, market
approval in 2021 still in prospect, price target of EUR 11.00 and BUY
rating confirmed
After MagForce AG announced the successful completion of stage 2a of the
pivotal study for the treatment of prostate cancer in the USA in February
2021, the company has published additional, [ … ]
Thu, 22.04.2021
Cardiol Therapeutics
The Company announced topline results from its Phase I Single and Multiple
Ascending Dose Clinical Trial of CardiolRx(TM). CardiolRx is a
pharmaceutically produced oral cannabidiol formulation being developed for
the treatment of acute and chronic inflammation associated with heart
disease. These results positively support Cardiol Therapeutics' pr [ … ]
Mon, 29.03.2021
Cardiol Therapeutics
GBC Research Watchlist: Cardiol Therapeutics Inc.
'The right moment to participate in this exciting growth story'
Cortalex - The purest form of CBD, no THC. It matters.
For many patient segments, CBD medication can be linked to the possibility
of becoming intoxicated by THC. For children, young adults under 25,
workers that cannot be intoxic [ … ]
Wed, 27.01.2021
Media and Games Invest plc
26/01/2021 - GBC Management Interview with Paul Echt, CFO of Media and
Games Invest Group
' We clearly want to reach the billion market capitalisation here and
continue to grow beyond that. '
Media and Games Invest (MGI) is a fast and profitable growing digital media
and games company. The company combines organic growth with targeted valuecre [ … ]
Thu, 14.01.2021
The NAGA Group AG
High growth momentum achieved in 2020; guidance for 2021 clearly above our
expectations; price target raised to EUR7.03 (previously: EUR4.30); BUY
rating
As expected, the preliminary figures of The NAGA Group AG (NAGA for short)
for the past financial year 2020 were characterised by very high growth
dynamic. Revenues of EUR25.9 million (PY: EUR6 [ … ]
Mon, 21.12.2020
Coreo AG
Planned financing successfully implemented, high liquidity available for
new investments, target price of EUR 2.35 and BUY rating confirmed
As announced after the cancellation of the bond issue by Coreo AG, the
company has successfully concluded a replacement financing. According to
the latest company announcement, the company has received a loa [ … ]
Fri, 18.12.2020
MagForce AG
Capital increase of EUR4.7m successfully implemented to finance growth
strategy, high share price potential, BUY rating confirmed
Since our last research study (see research study dated 12.11.2020), the
share price of MagForce AG has developed significantly positively. Within
just one month, the share price has risen significantly by approximate [ … ]
Wed, 16.12.2020
MBH Corporation plc
With four further acquisitions, our expectations were exceeded; price
target slightly increased; share clearly undervalued
MBH Corporation plc (MBH for short) has continued to show a high level of
acquisition activity compared to our last research report (see report dated
08.10.2020), as has been the case so far this year. On 30 October, the
com [ … ]
